Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?

Expert Review of Hematology
Ami B PatelMichael W Deininger

Abstract

With the discovery of imatinib mesylate nearly 20 years ago, tyrosine kinase inhibitors (TKIs) were found to be effective in chronic myeloid leukemia (CML). TKI therapy has since revolutionized the treatment of CML and has served as a paradigm of success for targeted drug therapy in cancer. Several new TKIs for CML have been approved over the last two decades that exhibit improved potency over imatinib and have different off-target profiles, providing options for individualized therapy selection. Areas covered: Current management of chronic phase CML, including guidance on the sequential use of imatinib and newer-generation TKIs and evolving treatment strategies such as TKI discontinuation. Relevant literature was identified by searching biomedical databases (i.e. PubMed) for primary research material. Expert commentary: Although survival outcomes have drastically improved for CML patients, treatment for CML has grown more complex with the introduction of next-generation TKIs and the advent of treatment-free remissions (TFR). Goals of therapy have shifted accordingly, with increased focus on improving quality of life, managing patient expectations and optimizing patient adherence.

References

Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Nov 8, 2001·Blood·F BonifaziUNKNOWN Swedish CML Study Group
Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
Sep 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alfonso Quintás-CardamaJorge Cortes
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Timothy HughesAndreas Hochhaus
Apr 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Deborah L WhiteTimothy P Hughes
May 28, 2010·Clinical Ophthalmology·Collin M McClellandPhilip L Custer
Jun 8, 2010·The New England Journal of Medicine·Giuseppe SaglioUNKNOWN ENESTnd Investigators
Jun 8, 2010·The New England Journal of Medicine·Hagop KantarjianMichele Baccarani
Dec 24, 2010·The New England Journal of Medicine·Claude PreudhommeUNKNOWN France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC)
Mar 23, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rüdiger HehlmannSusanne Saussele
Nov 1, 2011·Blood·Alice FabariusUNKNOWN Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study Group
Nov 10, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David MarinLetizia Foroni
Dec 20, 2011·Haematologica·Naoto TakahashiKazuma Ohyashiki
Jun 2, 2012·Blood·Rüdiger Hehlmann
Sep 6, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E CortesCarlo Gambacorti-Passerini
Jan 19, 2013·Leukemia·S MustjokiUNKNOWN Nordic CML Study Group (NCMLSG)
May 16, 2013·Biologics : Targets & Therapy·Gunhild Keller-von Amsberg, Philippe Schafhausen

❮ Previous
Next ❯

Citations

Jan 13, 2018·Frontiers in Bioengineering and Biotechnology·Raquel VinhasPedro V Baptista
Jul 26, 2017·Expert Review of Hematology·Andrés Gomez-de-LeónGuillermo J Ruiz-Arguelles
Apr 25, 2018·Current Hematologic Malignancy Reports·James A Kennedy, Gabriela Hobbs
Nov 24, 2019·Surgical Oncology Clinics of North America·Deborah B Doroshow, James H Doroshow

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology
Ebru Koca, İbrahim C Haznedaroğlu
Best Practice & Research. Clinical Haematology
Kendra Sweet, Javier Pinilla-Ibarz
Cancer Control : Journal of the Moffitt Cancer Center
Alfonso Quintás-CardamaJorge E Cortes
© 2022 Meta ULC. All rights reserved